Abstract: An indoline compound. Specifically disclosed is an application of a compound represented by formula (I) and pharmaceutically acceptable salts thereof in the preparation of drugs for treating related diseases.

Abstract: The present application discloses a class of guaianolide sesquiterpene lactone derivatives and pharmaceutical use thereof. The guaianolide sesquiterpene lactone derivative or a pharmaceutically acceptable salt thereof is shown as general formula I. In the present application, a class of novel guaianolide sesquiterpene lactone derivatives are found by structural optimization with abundant natural ingredients such as parthenolide and dehydrocostus lactone as raw materials, which derivatives have good inhibitory activity on the activation of the NLRP3 inflammasome, and the chemical stability, water solubility and oral bioavailability of which are significantly improved, and it is verified by experiments that the derivatives have inhibitory effects on the activity of the NLRP3 inflammasome and have potential pharmaceutical applications.

Abstract: Among the various aspects of the present disclosure is the provision of systems and methods of imaging using photoacoustic computed tomography.

Abstract: A salt form of a tetra-substituted olefin compound, a crystal of the compound and the salt, and a preparation method relating to a crystal of a compound represented by formula (I), a salt thereof, a crystal of the salt thereof, and a preparation method therefor.

Abstract: Disclosed are a salt form used as a CDC7 inhibitor and a crystal form thereof, and specifically disclosed is a compound represented by formula (II), a crystal form thereof, a preparation method thereof, and an application thereof in the preparation of a drug for preventing or treating tumors.

Abstract: A synthesis method of alpha-hydroxycarboxylic acid ester is provided. In the method, an alpha-hydroxycarboxylic acid and an alcohol are taken as raw materials, one or more of boric acid, metaboric acid, pyroboric acid, and boric anhydride is taken as a catalyst, and one of cyclohexane, toluene, benzene, and alcohols is taken as a water-carrying agent. A reaction temperature is kept in range of 100-160° C., produced water is separated by an oil-water separator, and the alpha-hydroxycarboxylic acid ester is synthesized directly. After an esterification reaction, the water-carrying agent and unreacted alcohol are distilled by vacuum fractionation to obtain a crude product, and refined alpha-hydroxycarboxylic acid ester is obtained by performing neutralization, water washing, and vacuum rectification on the crude product. The alpha-hydroxycarboxylic acid ester prepared by the method has high purity and light color, and can be used as green solvent, surfactant, chiral resolution agent and plasticizer.

Abstract: Disclosed is a type of indolo heptamyl oxime analog crystalline form as a PARP inhibitor and a method for preparing the same, specifically relating to a crystalline form of a compound of formula (I) and a method for preparing the same.

Abstract: An embodiment of the present disclosure provides a water outlet device including a first water outlet fixedly mounted on a worktable, a second water outlet detachably connected with the first water outlet or the worktable for an operator to hold, and a control unit for being mounted on the worktable and including a controller and a power source. The power source is electrically connected with the controller for supplying power for the controller. The controller is configured to control opening or closing of the first water outlet and/or the second water outlet.

Abstract: A pyrimidine ring compound represented by formula (III), or a pharmaceutically acceptable salt thereof, and an application thereof in preparation of a medication for treating related diseases.

Abstract: Disclosed is a class of compounds containing arylsultam, and specifically disclosed are a compound represented by formula (II), and a pharmaceutically acceptable salt or an isomer thereof.

Abstract: Disclosed in the present invention is a novel compound as FLT3 and AXL inhibitors. Specifically, disclosed are a compound represented by formula (I) and a pharmacologically acceptable salt thereof.

Abstract: Disclosed is a class of compounds containing arylsultam, and specifically disclosed are a compound represented by formula (II), and a pharmaceutically acceptable salt or an isomer thereof.

Abstract: Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a salt type and a crystal form (I) of a diazaspiropyran compound, and a preparation method therefor. Also disclosed is the use of the salt type and the crystal form in the preparation of drugs for treating related diseases.

Abstract: A faucet with a utensil flushing mechanism comprises a faucet mechanism, a water inlet mechanism, and the utensil flushing mechanism. The faucet mechanism comprises a tube body and a first water passage disposed at least partially in the tube body. The water inlet mechanism is connected to the first water passage. The utensil flushing mechanism is disposed on the faucet mechanism and comprises a nozzle configured to be in communication with the water inlet mechanism. The utensil flushing mechanism is movably disposed on the tube body, and the nozzle is configured to be controlled to be in different positions through movement of the utensil flushing mechanism.

Abstract: A water outlet device with water stop and flow rate control comprises a body, a water stop assembly, and a flow rate control assembly. The body comprises a water outflow passage. The flow rate control assembly and the water stop assembly are disposed on the body, first ends of the water stop assembly and the flow rate control assembly are respectively disposed in the water outflow passage, and second ends of the water stop assembly and the flow rate control assembly are exposed out of the body to respectively define a water stop operation end and a flow rate control end. The water stop assembly comprises a first shaft that is operatively connected to the water stop operation end. The flow rate control assembly comprises a second shaft that is operatively connected to the flow rate control end.

Abstract: Provided are a uracil compound represented by Formula (IV) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition of the same. Also provided is a use thereof as a c-MET/AXL inhibitor in preparing a c-MET/AXL-inhibiting drug or a drug for treating a tumor.

Abstract: The present disclosure discloses a faucet. The faucet comprises a faucet device, a waste disposer, a first control mechanism, and a second control mechanism. The faucet device comprises a first water passage and a second water passage. The first control mechanism comprises a first control valve disposed on the first water passage and at least controlling a turning on and off of the first water passage. The second control mechanism comprises a control switch and a second control valve. The second control valve is disposed on the second water passage and at least controls a turning on and off of the second water passage. The second water passage is connected with an ozone supply device to enable the second water passage to supply ozonated water, and the control switch is controlled to generate a first instruction to turn on the second control valve and the waste disposer.

Abstract: Disclosed are a pyrimidinyl group-containing tricyclic compound and applications thereof in preparing a cancer-treating medicament. Specifically disclosed are a compound as represented by formula (I), a pharmaceutically acceptable salt of same, or an isomer thereof.

Abstract: Disclosed is a biarylamide compound as a Pan-RAF kinase inhibitor, and specifically disclosed are a compound as shown in formula (III) and a pharmaceutically acceptable salt thereof.